



Research on HIV/AIDS Vaccine

Guest Editors:

Dr. Portia Chipo Mutevedzi

Child Health and Mortality
Prevention Surveillance
(CHAMPS), Emory University,
Atlanta, GA, USA

Dr. Nagesh Kolishetti

Department of Immunology and
Nano-Medicine, Herbert
Wertheim College of Medicine,
Florida International University,
Miami, FL 33199, USA

Deadline for manuscript
submissions:

31 May 2025

Message from the Guest Editors

The development and accessibility of highly active antiretroviral treatment (ART) represent a significant step, but suboptimal adherence and drug resistance remain major challenges. Millions of people living with HIV still lack access to ART. Although ART is essential in preventing HIV transmission, alone it cannot end the pandemic. Therefore, developing an HIV vaccine is a global health priority and the only way to put an end to the HIV and AIDS pandemic. This Special Issue highlights recent scientific and technical advancements made in this field, including correlates of protection, immune pathways, mechanisms for addressing ART unmet needs, and recent advances in novel prophylactic and therapeutic vaccines. We invite contributions including original reports, original observations, or reviews to highlight (i) correlates of protection, (ii) immune pathways after primary infection, (iii) mechanisms for addressing ART unmet needs such as persistent viral replication in compartments and reservoirs insensitive to ART, chronic immune activation, and the incomplete restoration of B and T cells, and (iv) recent advances in novel prophylactic and therapeutic vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com